These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21988494)

  • 1. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.
    Øzbay LA; Møller N; Juhl C; Bjerre M; Carstens J; Rungby J; Jørgensen KA
    Br J Clin Pharmacol; 2012 Apr; 73(4):536-45. PubMed ID: 21988494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of calcineurin inhibitors on insulin sensitivity and insulin secretion: a randomized crossover trial in uraemic patients.
    Ozbay LA; Møller N; Juhl C; Bjerre M; Carstens J; Rungby J; Jørgensen KA
    Diabet Med; 2012 Dec; 29(12):e440-4. PubMed ID: 23003106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.
    Øzbay LA; Smidt K; Mortensen DM; Carstens J; Jørgensen KA; Rungby J
    Br J Pharmacol; 2011 Jan; 162(1):136-46. PubMed ID: 20825407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of calcineurin inhibitors on prostanoid synthesis: a randomized cross-over study in healthy humans.
    Øzbay LA; Stubbe J; Jespersen B; Jensen BL
    Transpl Int; 2013 Feb; 26(2):131-7. PubMed ID: 23190385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells.
    Triñanes J; Rodriguez-Rodriguez AE; Brito-Casillas Y; Wagner A; De Vries APJ; Cuesto G; Acebes A; Salido E; Torres A; Porrini E
    Am J Transplant; 2017 Nov; 17(11):2829-2840. PubMed ID: 28432716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
    Zaltzman JS
    Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.
    Rathi M; Rajkumar V; Rao N; Sharma A; Kumar S; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Sakhuja V
    Transplant Proc; 2015 May; 47(4):1158-61. PubMed ID: 26036543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence for progressive deterioration in stimulated insulin secretion in renal transplant recipients after 12years tacrolimus exposure.
    Gelens MACJ; van Hooff JP; Usvyat L; Christiaans MH
    J Diabetes Complications; 2017 Sep; 31(9):1384-1388. PubMed ID: 28720321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus.
    Chakkera HA; Kudva Y; Kaplan B
    Clin Pharmacol Ther; 2017 Jan; 101(1):114-120. PubMed ID: 27804122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Effects of Voclosporin and Tacrolimus on Insulin Secretion From Human Islets.
    Kolic J; Beet L; Overby P; Cen HH; Panzhinskiy E; Ure DR; Cross JL; Huizinga RB; Johnson JD
    Endocrinology; 2020 Nov; 161(11):. PubMed ID: 32894758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
    Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
    Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients.
    David-Neto E; Lemos FC; Fadel LM; Agena F; Sato MY; Coccuza C; Pereira LM; de Castro MC; Lando VS; Nahas WC; Ianhez LE
    Transplantation; 2007 Jul; 84(1):50-5. PubMed ID: 17627237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
    Singh R; Srivastava A; Kapoor R; K Sharma R; D Mittal R
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
    Nasu R; Nannya Y; Shinohara A; Ichikawa M; Kurokawa M
    Ann Hematol; 2014 Jul; 93(7):1215-23. PubMed ID: 24590535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.